This inventor holds 2 USPTO granted patents. Top assignee: Takeda Pharmaceutical Company Limited. Active years: 2026.
Company Filing History:
Years Active: 2026
Title: Etsuko Shimobayashi: Innovator in Antisense Oligonucleotide Research
Introduction
Etsuko Shimobayashi is a prominent inventor based in Fujisawa, Japan. She has made significant contributions to the field of molecular biology, particularly in the development of antisense oligonucleotides. Her work focuses on innovative methods for splicing modulation, which has important implications for treating various diseases.
Latest Patents
Etsuko Shimobayashi holds a patent titled "Compositions and methods for splicing modulation of UNC13A." This patent describes antisense oligonucleotides designed to inhibit the inclusion of a cryptic exon into the mature mRNA of UNC13A. The patent also outlines pharmaceutical compositions that include these oligonucleotides and methods for treating UNC13A-associated diseases or conditions related to TDP-43 dysfunction.
Career Highlights
Etsuko is affiliated with Takeda Pharmaceutical Company Limited, where she continues to advance her research. Her work has garnered attention for its potential to impact therapeutic strategies in neurology and other fields.
Collaborations
Etsuko collaborates with Masahiro Nogami, contributing to the innovative research environment at Takeda. Their partnership exemplifies the collaborative spirit that drives scientific advancements.
Conclusion
Etsuko Shimobayashi's contributions to antisense oligonucleotide research highlight her role as a key innovator in the field. Her patent work and collaborations reflect her commitment to advancing medical science and improving patient outcomes.